“…Furthermore, these infections were cured with the same antibiotics used clinically to cure these infections (Kaito et al, 2002; Hamamoto et al, 2004). Since then, silkworms have been utilized to study pathogenic bacterial toxins (Hossain et al, 2006); evaluate the target specificity of antibacterial agents (Kurokawa et al, 2009); identify novel S. aureus virulence genes (Kaito et al, 2005; Miyazaki et al, 2012); and identify novel probiotic bacteria that promote survival during P. aeruginosa infection (Nishida et al, 2016). Additionally, infection model of multiple pathogenic microorganisms Stenotrophomonas maltophilia (Hamamoto et al, 2004); Vibrio vulnificus (Yamamoto et al, 2016); Vibrio cholera (Kaito et al, 2002); Candida tropicalis (Hamamoto et al, 2004); Candida albicans (Hamamoto et al, 2004); Aspergillus fumigatus (Nakamura et al, 2017a); Cryptococcus neoformans (Matsumoto et al, 2012); and laboratory generated vancomycin-resistant S. aureus VR7 (Tabuchi et al, 2017) have been developed and the success of the antimicrobial to rescue the silkworms from the effect of pathogens have been reported (Table 2).…”